CDA-2, a urinary preparation, inhibits lung cancer development through the suppression of NF-kappaB activation in myeloid cell.
CDA-2 (cell differentiation agent 2), a urinary preparation, has potent anti- proliferative and pro-apoptotic properties in cancer cells. However, the mechanisms of tumor inhibitory action of CDA-2 are far from clear, and especially there was no report on lung cancer. Here we demonstrate that CDA-2...
Main Authors: | Xuan Wang, Cui-Min Jiang, Hai-Ying Wan, Jun-Lu Wu, Wen-Qiang Quan, Robert Bals, Kai-Yin Wu, Dong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3524164?pdf=render |
Similar Items
-
NF-kappaB in Lung Tumorigenesis
by: William N. Rom, et al.
Published: (2011-12-01) -
NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts.
by: Smith, C, et al.
Published: (2001) -
Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin.
by: Brian K Bednarski, et al.
Published: (2009-09-01) -
Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.
by: Andreakos, E, et al.
Published: (2006) -
NF-kappaB mediates tumor necrosis factor alpha-induced expression of optineurin, a negative regulator of NF-kappaB.
by: Cherukuri Sudhakar, et al.
Published: (2009-01-01)